 <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<!-- saved from url=(0014)about:internet -->
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
<meta name="description" content="" />
<meta name="keywords" content="" />
<meta name="author" content="" />
<link rel="stylesheet" type="text/css" href="css/style.css" media="screen" />
<link rel="stylesheet" type="text/css" href="css/blockade.css" media="screen" />

<!--[if lt IE 7.]>
	<script defer type="text/javascript" src="js/pngfix.js"></script>
<![endif]-->
<title>
</title>
<script type="text/javascript" src="js/jquery-1.6.1.min.js"></script>
<script type="text/javascript" src="js/jquery.simplemodal.js"></script>




<script type="text/javascript" >
function show_reference() {
	$('#references-wrapper').modal({opacity:25});
}
</script>

<!-- Is there an overlay (used for gif animation) -->


<script type="text/javascript">
$(document).ready(function() {
  // Handler for .ready() called.
	setTimeout("blockade1()",2000);
});

function blockade1() {
	$('#blockade_sprite1_jpg').fadeIn( 'slow', function() {
		setTimeout("blockade2()",2000);	}
	 )
}

function blockade2() {
	$('#blockade1').css( 'color','#923222' );
	$('#blockade_sprite0_jpg').fadeIn( 'slow', function() {
		setTimeout("blockade3()",2000);	}
	 )
}

function blockade3() {
	$('#blockade2').css( 'color','#923222' );
	$('#blockade_sprite4_jpg').fadeIn( 'slow', function() {
		setTimeout("blockade4()",2000);	}
	 )
}

function blockade4() {
	$('#blockade3').css( 'color','#923222' );
	$('#blockade_sprite3_jpg').fadeIn( 'slow', function() {
		setTimeout("blockade5()",2000);	}
	 )
}


function blockade5() {
	$('#blockade4').css( 'color','#923222' );
	$('#blockade_sprite2_jpg').fadeIn( 'slow' )
}



</script>

</head> 

<body>
<div id="wrapper" class="white">

<a href='page3.html' id='home' class='toplinks'>Home</a>
<a href='javascript:show_reference()' id='references' class='toplinks'>References</a>

<div id='leftarrow'>
		<a href='page21.html'><img src='images/left-arrow-active.png'></a>
</div>

<div id='rightarrow'>
		<a href='page23.html'><img src='images/right-arrow-active.png'></a>
</div>
<div id='progress'>

    <div id='progress-status' style="width:171px;">
    </div>
    <div id='progress-bar' style=" background: url('images/progress-bar-2.png')  no-repeat scroll 0 0 transparent;">

    </div>
</div> <!-- Progress Bar -->


	<div id="title">Selective costimulation blockade </div>

	<div id="title2">Belatacept selectively binds to CD80 and CD86, blocking the interaction with CD28<span class='footnote'>11</span> </div>

<!-- Content begin -->

<!-- Content end -->


<!-- Quiz Begin -->
<!-- Quiz end -->


<!-- Is there Audio? -->


<div class="blockade_sprites" id="blockade_sprite0_jpg"></div> 
 
<div class="blockade_sprites" id="blockade_sprite1_jpg"></div> 
 
<div class="blockade_sprites" id="blockade_sprite2_jpg"></div> 
 
<div class="blockade_sprites" id="blockade_sprite3_jpg"></div> 
 
<div class="blockade_sprites" id="blockade_sprite4_jpg"></div> 
 
<div class="blockade_sprites" id="blockade_sprite5_jpg"></div> 

<div id="blockade_text">
<div class="text1">
<div style="padding-bottom:10px;">
<b>
The result:</b> T-cell apoptosis and prevention<br/>of T-cell–mediated rejection<span class="footnote">11</span>
</div>
<div style="font-weight:bold; font-size:13px; padding-bottom:10px;">
A quick look back at how<br/>belatacept differs from other<br/>immunosuppressive agents
</div>

<ul class="blockade_ul">
<li>
<div id="blockade1" class="text1"><b><i>Basiliximab</i></b> binds to and blocks the<br/> interleukin 2 receptor (IL-2R) on activated T<br/> cells, thus inhibiting IL-2–induced T-cell<br/> proliferation<span class="footnote">13</span> 
</div>
</li>
<li>
<div id="blockade2" class="text1"><b><i>CNIs</i></b> block the rate-limiting protein<br/> phosphatase, calcineurin, needed for the signal<br/> 1 transduction pathway<span class="footnote">13</span> 
</div>
</li>

<li>
<div id="blockade3" class="text1"><b><i>MPA</i></b> inhibits inosine monophosphate<br/> dehydrogenase (IMPDH), the rate-limiting<br/> enzyme in purine synthesis<span class="footnote">13</span> 
</div>
</li>
<div id="blockade4" class="text1"><b><i>Sirolimus and everolimus</i></b> inhibit the protein<br/> kinase, mTOR, blocking downstream IL-2<br/> effects and inhibiting cell-cycle progression<span class="footnote">13</span> 
</div>
</li>

</ul>

</div>


<div id="footer">
<p>Information contained in this module is for educational purposes only and is not to be discussed with customers.<br/>
This information is for internal use only and is not to be left with, detailed from, or shown to anyone outside of Novartis Pharmaceuticals Corporation.</p>
</div>

 



</div> <!-- End #wrapper -->

		

		<div id="references-wrapper">
<div id="references-text1">
  <p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References:</strong></p>
  <ol>
    <li><span>Vincenti F, Charpentier  B, Vanrenterghem Y, et al. A phase III study of belatacept-based  immunosuppression regimens versus cyclosporine in renal transplant recipients  (BENEFIT study). <em>Am J</em> <em>Transplant</em>.  2010;10(3):535-546.</span></li>

    <li><span>Durrbach A, Pestana JM,  Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney  transplants from extended criteria donors (BENEFIT-EXT study). <em>Am J</em> <em>Transplant</em>.  2010;10(3):547-557.</span></li>
    <li><span>Durrbach A, Francois H,  Beaudreuil S, et al. Advances in immunosuppression for renal transplantation. <em>Nat Rev Nephrol</em>. 2010;6(3):160-167.</span></li>
    <li><span>Organ transplant history.  The New York Organ Donor Network Web site.  http://www.donatelifeny.org/all-about-transplantation/organ-transplant-history.  Accessed May 5, 2011.</span></li>
    <li><span>Maxwell  RA, Eckhardt SB. <em>Drug Discovery: A  Casebook and Analysis.</em> Clifton, NJ: The Humana Press Inc.; 1990:95.</span></li>

    <li><span>Tribe  HT. The discovery and development of cyclosporin. <em>Mycologist</em>. 1998;12:20-22.</span></li>
    <li><span>Schuler W, Sedrani R, Cottens S, et al. SDZ  RAD, a new rapamycin derivative: pharmacological properties in vitro and in  vivo. <em>Transplantation</em>.  1997;64(1):36-42.</span></li>
    <li><span>US  Food and Drug Administration. Myfortic<sup>&reg;</sup> (mycophenolic acid)  Delayed-Release Tablets approval letter. NDA 50-791. 2004. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/50-791_Myfortic.cfm.  Accessed May 5, 2011.</span></li>
    <li><span>US Food and Drug  Administration. Zortress (everolimus) Tablets approval letter. NDA 21560. 2010.  http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021560s000_zortress_toc.cfm.  Accessed May 5, 2010.</span></li>

    <li><span>US Renal Data System. USRDS 2009 Annual Data Report: Atlas of
Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.  </span></li>
</ol>
</div>
<div id="references-text2">
<br/>
<ol START=11>
    <li><span>Vincenti  F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal  transplantation. <em>N Engl J  Med</em>. 2005;353(8):770-781.</span></li>
    <li><span>Data  on file. [US Transplant Market Final Presentation, March 17, 2010]. Novartis Pharmaceuticals  Corp; 2010.</span></li>
    <li><span>Halloran  PF. Immunosuppressive drugs for kidney transplantation. <em>N Engl J Med</em>.  2004;351(26):2715-2729.</span></li>

    <li><span>Larsen  CP, Griny&oacute; J, Medina-Pestana J, et al. Belatacept-based regimens versus a  cyclosporine A-based regimen in kidney transplant recipients: 2-year results  from the BENEFIT and BENEFIT-EXT studies. <em>Transplantation</em>.  2010;90(12):1528-1535.</span></li>
    <li><span>Vincenti  F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT: a phase III  study of belatacept vs cyclosporine in kidney transplant recipients [ATC Abstract  227]. <em>Am J</em> <em>Transplant</em>. 2011;11(suppl 2):99.</span></li>
    <li><span>US  Food and Drug Administration. Belatacept (BMS-224818) FDA's Cardiovascular and Renal Drugs Advisory Committee briefing document  for March 2010 meeting. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM201859.pdf. <cite>Accessed May 5, 2011.</cite></span></li>

    <li><span>Hirsch  HH. Polyomavirus BK nephropathy: a (re-)emerging complication in renal  transplantation. <em>Am J</em> <em>Transplant</em>.  2002;2(1):25-30.</span></li>
    <li><span>Medina  Pestana J, Grinyo J, Vanrenterghem Y, et al. Belatacept compared with  cyclosporine in renal allograft recipients of extended criteria donor kidneys:  3-year outcomes from the phase III BENEFIT-EXT trial [ATC Abstract 1088]. <em>Am J</em> <em>Transplant</em>.  2011;11(suppl 2):349.</span></li>
    <li><span>Larsen  C, Grinyo J, Medina Pestana J, et al. 3-year safety profile of belatacept in  kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [ATC Abstract  228]. <em>Am J</em> <em>Transplant</em>. 2011;11(suppl 2):99-100.</span></li>

  </ol>
</div>
</div>
        
        
        
 
		<!-- preload the images -->
		<div style='display:none'>
			<img src='images/close_icon.png' alt='' />
		</div>
</body>
</html> 

